FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597431639> ?p ?o ?g. }

• W2597431639 endingPage "263" @default.
• W2597431639 startingPage "263" @default.
• W2597431639 abstract "Abstract In individuals with chronic inflammatory diseases, such as cancer or rheumatoid arthritis, constitutive signaling through ALK2, a member of the bone morphogenetic protein (TGFβ/BMP) receptor family, leads to debilitating anemia, commonly referred to as anemia of chronic disease (ACD). Activation of ALK2, like other members of the BMP receptor family, leads to the phosphorylation and activation of SMAD family transcription factors via signal transduction and subsequent activation of gene expression. Activation of ALK2 in the liver induces the SMAD-driven transcription of the peptide hormone hepcidin which, by promoting the degradation of the iron transporter ferroportin, leads to reduced serum iron levels and subsequent functional anemia. Lowering constitutively elevated hepcidin levels by inhibiting ALK2 kinase activity is a potentially viable therapeutic strategy for ACD. Current therapeutic approaches for ACD rely on transfusions, intravenous iron and the use of erythropoietin-based therapies, none of which address the underlying pathological deficit of functionally low iron levels. TP-0184 is a small-molecule, selective inhibitor of ALK2 kinase activity (IC50 = 5 nM). TP-0184 has demonstrated profound preclinical activity in three mouse efficacy models for ACD. In model 1, TP-0184 reversed hepcidin induction in mice treated with turpentine oil. In model 2, TP-0184 abrogated reductions in hemoglobin and total red blood cell counts induced by intraperitoneal injection with heat-inactivated Brucella abortus. In model 3, TP-0184 reversed elevated hepcidin levels in TC-1 tumor bearing mice. Plasma and liver pharmacokinetics in mice revealed that TP-0184 has a high volume of distribution (Vd = 30.8) and accumulates at high concentrations in the liver (Cmax of 292 mM following a single oral dose of at 20 mg/kg). In rat multi-dose tolerability studies, TP-0184 caused no adverse effects when dosed at 200 mg/kg for 7 days, far exceeding the dose levels required to produce efficacy (25 mg/kg). These data suggest that favorable distribution to the liver may play a significant role in the preclinical efficacy of TP-0184 and provide evidence of a significant therapeutic window. Collectively these studies support the clinical evaluation of TP-0184 as an alternative treatment for ACD. Disclosures Peterson: Tolero Pharmaceuticals: Employment. Kim:Tolero Pharmaceuticals: Employment. Haws:Tolero Pharmaceuticals: Employment. Whatcott:Tolero Pharmaceuticals: Employment. Siddiqui-Jain:Tolero Pharmaceuticals: Employment. Bearss:Tolero Pharmaceuticals: Employment, Equity Ownership, Patents & Royalties. Warner:Tolero Pharmaceuticals: Employment, Equity Ownership, Patents & Royalties." @default.
• W2597431639 created "2017-04-07" @default.
• W2597431639 creator A5032408645 @default.
• W2597431639 creator A5032831840 @default.
• W2597431639 creator A5038673041 @default.
• W2597431639 creator A5042129518 @default.
• W2597431639 creator A5055924314 @default.
• W2597431639 creator A5059055507 @default.
• W2597431639 creator A5089291656 @default.
• W2597431639 date "2016-12-02" @default.
• W2597431639 modified "2023-10-18" @default.
• W2597431639 title "The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease" @default.
• W2597431639 doi "https://doi.org/10.1182/blood.v128.22.263.263" @default.
• W2597431639 hasPublicationYear "2016" @default.
• W2597431639 type Work @default.
• W2597431639 sameAs 2597431639 @default.
• W2597431639 citedByCount "3" @default.
• W2597431639 countsByYear W25974316392019 @default.
• W2597431639 countsByYear W25974316392021 @default.
• W2597431639 countsByYear W25974316392023 @default.
• W2597431639 crossrefType "journal-article" @default.
• W2597431639 hasAuthorship W2597431639A5032408645 @default.
• W2597431639 hasAuthorship W2597431639A5032831840 @default.
• W2597431639 hasAuthorship W2597431639A5038673041 @default.
• W2597431639 hasAuthorship W2597431639A5042129518 @default.
• W2597431639 hasAuthorship W2597431639A5055924314 @default.
• W2597431639 hasAuthorship W2597431639A5059055507 @default.
• W2597431639 hasAuthorship W2597431639A5089291656 @default.
• W2597431639 hasConcept C126322002 @default.
• W2597431639 hasConcept C170493617 @default.
• W2597431639 hasConcept C203014093 @default.
• W2597431639 hasConcept C2775989426 @default.
• W2597431639 hasConcept C2776710925 @default.
• W2597431639 hasConcept C2776768029 @default.
• W2597431639 hasConcept C2778248108 @default.
• W2597431639 hasConcept C2778534260 @default.
• W2597431639 hasConcept C2781080636 @default.
• W2597431639 hasConcept C31102739 @default.
• W2597431639 hasConcept C502942594 @default.
• W2597431639 hasConcept C71924100 @default.
• W2597431639 hasConcept C98274493 @default.
• W2597431639 hasConceptScore W2597431639C126322002 @default.
• W2597431639 hasConceptScore W2597431639C170493617 @default.
• W2597431639 hasConceptScore W2597431639C203014093 @default.
• W2597431639 hasConceptScore W2597431639C2775989426 @default.
• W2597431639 hasConceptScore W2597431639C2776710925 @default.
• W2597431639 hasConceptScore W2597431639C2776768029 @default.
• W2597431639 hasConceptScore W2597431639C2778248108 @default.
• W2597431639 hasConceptScore W2597431639C2778534260 @default.
• W2597431639 hasConceptScore W2597431639C2781080636 @default.
• W2597431639 hasConceptScore W2597431639C31102739 @default.
• W2597431639 hasConceptScore W2597431639C502942594 @default.
• W2597431639 hasConceptScore W2597431639C71924100 @default.
• W2597431639 hasConceptScore W2597431639C98274493 @default.
• W2597431639 hasIssue "22" @default.
• W2597431639 hasLocation W25974316391 @default.
• W2597431639 hasOpenAccess W2597431639 @default.
• W2597431639 hasPrimaryLocation W25974316391 @default.
• W2597431639 hasRelatedWork W1606051092 @default.
• W2597431639 hasRelatedWork W1976019480 @default.
• W2597431639 hasRelatedWork W2028695639 @default.
• W2597431639 hasRelatedWork W2078783949 @default.
• W2597431639 hasRelatedWork W2597431639 @default.
• W2597431639 hasRelatedWork W2900005918 @default.
• W2597431639 hasRelatedWork W3026338626 @default.
• W2597431639 hasRelatedWork W3100975179 @default.
• W2597431639 hasRelatedWork W3151039178 @default.
• W2597431639 hasRelatedWork W2047396855 @default.
• W2597431639 hasVolume "128" @default.
• W2597431639 isParatext "false" @default.
• W2597431639 isRetracted "false" @default.
• W2597431639 magId "2597431639" @default.
• W2597431639 workType "article" @default.